Compounds > erlotinib
Page last updated: 2024-09-05

erlotinib and fasudil

erlotinib has been researched along with fasudil in 6 studies

Compound Research Comparison

Studies
(erlotinib)		Trials
(erlotinib)		Recent Studies (post-2010)
(erlotinib)		Studies
(fasudil)		Trials
(fasudil)		Recent Studies (post-2010) (fasudil)
221018096540552

Protein Interaction Comparison

ProteinTaxonomyerlotinib (IC50)fasudil (IC50)
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunitBos taurus (cattle)2.28
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunitBos taurus (cattle)2.28
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunitBos taurus (cattle)2.28
Chain I, cAMP-dependent protein kinase inhibitor alphasynthetic construct2.28
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunitBos taurus (cattle)2.28
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunitBos taurus (cattle)2.28
Chain I, cAMP-dependent protein kinase inhibitor alphasynthetic construct2.28
Rho-associated protein kinase 2Homo sapiens (human)0.5296
Ribosomal protein S6 kinase alpha-5Homo sapiens (human)5
cAMP-dependent protein kinase catalytic subunit alphaBos taurus (cattle)1.8042
C-C motif chemokine 2Homo sapiens (human)6.9183
cAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)4.58
cAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)4.58
cAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)4.58
Protein kinase C epsilon typeHomo sapiens (human)3
Rho-associated protein kinase 1Homo sapiens (human)1.1469
Myosin light chain kinase, smooth muscleHomo sapiens (human)3.6
Serine/threonine-protein kinase N1Homo sapiens (human)1.7
Serine/threonine-protein kinase N2Homo sapiens (human)1.8533
Rho-associated protein kinase 2Bos taurus (cattle)1.8042
Rho-associated protein kinase 2Rattus norvegicus (Norway rat)1.9

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Al-Mazaideh, GM; Erdmann, F; Göllner, C; Rohe, A; Schmidt, M; Sippl, W; Wichapong, K1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1

Other Studies

6 other study(ies) available for erlotinib and fasudil

ArticleYear
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
    European journal of medicinal chemistry, 2013, Volume: 61

    Topics: Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Glycolipids; Humans; Membrane Proteins; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship

2013
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023